Fractalkine as an Important Target of Aspirin in the Prevention of Atherogenesis
Authors:
- 23 December 2009
- journal article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 24 (1) , 1-3
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Aspirin Inhibits Fractalkine Expression in Atherosclerotic Plaques and Reduces Atherosclerosis in ApoE Gene Knockout MiceCardiovascular Drugs and Therapy, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Fractalkine Deficiency Markedly Reduces Macrophage Accumulation and Atherosclerotic Lesion Formation in CCR2 −/− MiceCirculation, 2008
- Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaquesJournal of Clinical Investigation, 2007
- Aspirin Induces Apoptosis through the Inhibition of Proteasome FunctionJournal of Biological Chemistry, 2006
- Aspirin Attenuates the Initiation but Not the Progression of Atherosclerosis in Apolipoprotein E‐Deficient Mice Fed a High‐Fat, High‐Cholesterol DietBasic & Clinical Pharmacology & Toxicology, 2004
- Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout MiceCirculation, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Inhibition of NF-κB by Sodium Salicylate and AspirinScience, 1994
- Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin.Stroke, 1992